Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AGE NASDAQ:ANEB NASDAQ:CNTB NASDAQ:PEPG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGEAgeX Therapeutics$4.54$11.07▼$35.71$11.99M1.183,849 shs3,700 shsANEBAnebulo Pharmaceuticals$1.66-6.2%$1.29$0.80▼$3.08$72.72M-0.9819,278 shs1,052 shsCNTBConnect Biopharma$1.52+32.2%$0.90$0.51▼$1.60$63.90M-0.261,110 shs804,408 shsPEPGPepGen$1.26+0.8%$1.40$0.88▼$19.30$40.90M1.16846,825 shs261,890 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGEAgeX Therapeutics0.00%0.00%0.00%0.00%0.00%ANEBAnebulo Pharmaceuticals-6.21%-2.64%+43.10%+70.22%-28.45%CNTBConnect Biopharma+32.17%+33.92%+85.59%+143.20%+18.75%PEPGPepGen+0.80%+3.28%-13.10%+11.50%-92.56%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGEAgeX TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AANEBAnebulo Pharmaceuticals2.7385 of 5 stars3.53.00.00.03.81.70.0CNTBConnect Biopharma3.1706 of 5 stars3.53.00.00.03.12.50.6PEPGPepGen3.1137 of 5 stars3.24.00.00.01.72.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGEAgeX Therapeutics 0.00N/AN/AN/AANEBAnebulo Pharmaceuticals 3.00Buy$5.50231.33% UpsideCNTBConnect Biopharma 3.00Buy$7.00360.53% UpsidePEPGPepGen 2.33Hold$7.67508.47% UpsideCurrent Analyst Ratings BreakdownLatest AGE, ANEB, PEPG, and CNTB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2025CNTBConnect BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$7.005/29/2025PEPGPepGenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $8.005/15/2025ANEBAnebulo PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $3.005/9/2025PEPGPepGenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $14.00(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGEAgeX Therapeutics$140K0.00N/AN/A($16.07) per share0.00ANEBAnebulo PharmaceuticalsN/AN/AN/AN/A$0.15 per shareN/ACNTBConnect Biopharma$26.03M3.24N/AN/A$1.67 per share0.91PEPGPepGenN/AN/AN/AN/A$3.64 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGEAgeX Therapeutics-$14.80M-$13.03N/AN/AN/A-10,424.65%N/A-120.90%N/AANEBAnebulo Pharmaceuticals-$8.20M-$0.26N/A∞N/AN/A-90.11%-84.53%9/23/2025 (Estimated)CNTBConnect Biopharma-$15.63MN/A0.00N/AN/AN/AN/AN/A9/5/2025 (Estimated)PEPGPepGen-$89.98M-$3.13N/AN/AN/AN/A-81.26%-63.65%8/6/2025 (Estimated)Latest AGE, ANEB, PEPG, and CNTB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025CNTBConnect Biopharma-$0.26-$0.19+$0.07-$0.19N/AN/A5/13/2025Q3 2025ANEBAnebulo Pharmaceuticals-$0.05-$0.04+$0.01-$0.04N/AN/A5/8/2025Q1 2025PEPGPepGen-$0.72-$0.92-$0.20-$0.92N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGEAgeX TherapeuticsN/AN/AN/AN/AN/AANEBAnebulo PharmaceuticalsN/AN/AN/AN/AN/ACNTBConnect BiopharmaN/AN/AN/AN/AN/APEPGPepGenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGEAgeX TherapeuticsN/A0.130.36ANEBAnebulo PharmaceuticalsN/A25.2925.29CNTBConnect Biopharma0.0110.2510.25PEPGPepGenN/A4.954.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGEAgeX Therapeutics12.50%ANEBAnebulo Pharmaceuticals28.40%CNTBConnect Biopharma58.72%PEPGPepGen58.01%Insider OwnershipCompanyInsider OwnershipAGEAgeX Therapeutics6.50%ANEBAnebulo Pharmaceuticals80.60%CNTBConnect Biopharma22.60%PEPGPepGen5.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGEAgeX Therapeutics51.08 million1.01 millionNot OptionableANEBAnebulo Pharmaceuticals441.08 million7.97 millionNot OptionableCNTBConnect Biopharma11055.56 million43.00 millionOptionablePEPGPepGen3032.72 million31.02 millionNot OptionableAGE, ANEB, PEPG, and CNTB HeadlinesRecent News About These CompaniesPepGen Inc. Class Action: Levi & Korsinsky Reminds PepGen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 8, 2025 – PEPGJuly 11 at 4:24 PM | globenewswire.comSHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGenJuly 11 at 10:08 AM | globenewswire.comClass Action Filed Against PepGen Inc. (PEPG) Seeking Recovery for Investors - Contact Levi & KorsinskyJuly 11 at 9:00 AM | prnewswire.comPepGen Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before August 8, 2025 to Discuss Your Rights – PEPGJuly 10 at 4:56 PM | globenewswire.comPepGen Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before August 8, 2025 to Discuss Your Rights - PEPGJuly 10 at 9:00 AM | prnewswire.comPepGen Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before August 8, 2025 to Discuss Your Rights – PEPG - MorningstarJuly 9 at 8:37 PM | morningstar.comMPepGen Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. August 8, 2025 Deadline to file Lead Plaintiff Motion.July 9 at 6:46 PM | globenewswire.comROSEN, SKILLED INVESTOR COUNSEL, Encourages PepGen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PEPGJuly 9 at 3:32 PM | globenewswire.comPEPG Investors Have Opportunity to Lead PepGen Inc. Securities Fraud Lawsuit with the Schall Law FirmJuly 9 at 9:45 AM | prnewswire.comPEPG INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that PepGen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJuly 8, 2025 | globenewswire.comLevi & Korsinsky Reminds PepGen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 8, 2025 – PEPGJuly 8, 2025 | globenewswire.comPEPG Investors Have the Opportunity to Lead the PepGen Securities Fraud Lawsuit with Faruqi & Faruqi, LLPJuly 8, 2025 | prnewswire.comLevi & Korsinsky Reminds PepGen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 8, 2025 - PEPGJuly 8, 2025 | prnewswire.comPepGen Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before August 8, 2025 to Discuss Your Rights – PEPGJuly 7, 2025 | globenewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers - PEPGJuly 7, 2025 | prnewswire.comPEPGEN INC. (NASDAQ: PEPG) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds PepGen Inc. Investors of Upcoming DeadlineJuly 7, 2025 | globenewswire.comPepGen Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - PEPGJuly 7, 2025 | prnewswire.comROSEN, SKILLED INVESTOR COUNSEL, Encourages PepGen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PEPGJuly 6, 2025 | globenewswire.comPEPG Investors Have Opportunity to Lead PepGen Inc. Securities Fraud LawsuitJuly 6, 2025 | prnewswire.comSHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGenJuly 6, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy Quantum Computing Inc. Is the Quiet Winner in Quantum StocksBy Jeffrey Neal Johnson | June 18, 2025View Why Quantum Computing Inc. Is the Quiet Winner in Quantum StocksAnalysts Supercharge AMD Stock Ahead of Q2 AI CatalystBy Thomas Hughes | June 26, 2025View Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst2 Under the Radar Space & Defense Stocks With Huge PotentialBy Leo Miller | July 1, 2025View 2 Under the Radar Space & Defense Stocks With Huge PotentialTop 3 Bank Stocks to Watch as Fed Rate Cuts LoomBy Chris Markoch | June 25, 2025View Top 3 Bank Stocks to Watch as Fed Rate Cuts Loom3 Growth Stocks Too Small for Institutions to BuyBy Gabriel Osorio-Mazilli | June 19, 2025View 3 Growth Stocks Too Small for Institutions to BuyAGE, ANEB, PEPG, and CNTB Company DescriptionsAgeX Therapeutics NYSE:AGEAgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology. AgeX Therapeutics, Inc. has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. The company was incorporated in 2017 and is based in Alameda, California.Anebulo Pharmaceuticals NASDAQ:ANEB$1.66 -0.11 (-5.93%) As of 07/11/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.Connect Biopharma NASDAQ:CNTB$1.52 +0.37 (+32.17%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$1.52 -0.01 (-0.33%) As of 07/11/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.PepGen NASDAQ:PEPG$1.26 +0.01 (+0.80%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$1.30 +0.04 (+3.49%) As of 07/11/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/07 - 07/11 The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
